TY - JOUR
T1 - United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument
AU - Revicki, Dennis A.
AU - King, Madeleine T.
AU - Viney, Rosalie
AU - Pickard, A. Simon
AU - Mercieca-Bebber, Rebecca
AU - Shaw, James W.
AU - Müller, Fabiola
AU - Norman, Richard
N1 - Funding Information: Multi-Attribute Utility in Cancer (MAUCa) Consortium members: Neil Aaronson, John Brazier, David Cella, Dan Costa, Peter Fayers, Peter Grimison, Monika Janda, Georg Kemmler, Madeleine King (Chair), Helen McTaggart-Cowan, Rebecca Mercieca-Bebber, Richard Norman, Stuart Peacock, Simon Pickard, Donna Rowen, Galina Velikova, Rosalie Viney, Deborah Street, Tracey Young, and the European Organisation for Research and Treatment of Cancer. DAR receives research funding support from and consulting for Bristol Myers Squibb, Allergan, Amgen, and Abbvie. JWS is an employee and shareholder of Bristol Myers Squibb. ASP is a member of the EuroQol group, developers of the EQ-5D, and serves as a paid consultant through Second City Outcomes Research LLC for the health care/pharmaceutical industry. RN and RV are members of the EuroQol Group. FM and RMB have no conflicts of interest or financial disclosures to declare. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support for this study was provided entirely by a contract with Bristol Myers Squibb. The funding agreement ensured the authors? independence in designing the study, interpreting the data, writing, and publishing the report. Funding Information: DAR receives research funding support from and consulting for Bristol Myers Squibb, Allergan, Amgen, and Abbvie. JWS is an employee and shareholder of Bristol Myers Squibb. ASP is a member of the EuroQol group, developers of the EQ-5D, and serves as a paid consultant through Second City Outcomes Research LLC for the health care/pharmaceutical industry. RN and RV are members of the EuroQol Group. FM and RMB have no conflicts of interest or financial disclosures to declare. The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Financial support for this study was provided entirely by a contract with Bristol Myers Squibb. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report. Publisher Copyright: © The Author(s) 2021.
PY - 2021/5
Y1 - 2021/5
N2 - Background: The EORTC QLU-C10D is a multiattribute utility measure derived from the cancer-specific quality-of-life questionnaire, the EORTC QLQ-C30. The QLU-C10D contains 10 dimensions (physical, role, social and emotional functioning, pain, fatigue, sleep, appetite, nausea, bowel problems). The objective of this study was to develop a United States value set for the QLU-C10D. Methods: A US online panel was quota recruited to achieve a representative sample for sex, age (≥18 y), race, and ethnicity. Respondents undertook a discrete choice experiment, each completing 16 choice-pairs, randomly assigned from a total of 960 choice-pairs. Each pair included 2 QLU-C10D health states and duration. Data were analyzed using conditional logistic regression, parameterized to fit the quality-adjusted life-year framework. Utility weights were calculated as the ratio of each dimension-level coefficient to the coefficient for life expectancy. Results: A total of 2480 panel members opted in, 2333 (94%) completed at least 1 choice-pair, and 2273 (92%) completed all choice-pairs. Within dimensions, weights were generally monotonic. Physical functioning, role functioning, and pain were associated with the largest utility weights. Cancer-specific dimensions, such as nausea and bowel problems, were associated with moderate utility decrements, as were general issues such as problems with emotional functioning and social functioning. Sleep problems and fatigue were associated with smaller utility decrements. The value of the worst health state was 0.032, which was slightly greater than 0 (equivalent to being dead). Conclusions: This study provides the US-specific value set for the QLU-C10D. These estimated health state scores, based on responses to the EORTC QLQ-C30 questionnaire, can be used to evaluate the cost-utility of oncology treatments.
AB - Background: The EORTC QLU-C10D is a multiattribute utility measure derived from the cancer-specific quality-of-life questionnaire, the EORTC QLQ-C30. The QLU-C10D contains 10 dimensions (physical, role, social and emotional functioning, pain, fatigue, sleep, appetite, nausea, bowel problems). The objective of this study was to develop a United States value set for the QLU-C10D. Methods: A US online panel was quota recruited to achieve a representative sample for sex, age (≥18 y), race, and ethnicity. Respondents undertook a discrete choice experiment, each completing 16 choice-pairs, randomly assigned from a total of 960 choice-pairs. Each pair included 2 QLU-C10D health states and duration. Data were analyzed using conditional logistic regression, parameterized to fit the quality-adjusted life-year framework. Utility weights were calculated as the ratio of each dimension-level coefficient to the coefficient for life expectancy. Results: A total of 2480 panel members opted in, 2333 (94%) completed at least 1 choice-pair, and 2273 (92%) completed all choice-pairs. Within dimensions, weights were generally monotonic. Physical functioning, role functioning, and pain were associated with the largest utility weights. Cancer-specific dimensions, such as nausea and bowel problems, were associated with moderate utility decrements, as were general issues such as problems with emotional functioning and social functioning. Sleep problems and fatigue were associated with smaller utility decrements. The value of the worst health state was 0.032, which was slightly greater than 0 (equivalent to being dead). Conclusions: This study provides the US-specific value set for the QLU-C10D. These estimated health state scores, based on responses to the EORTC QLQ-C30 questionnaire, can be used to evaluate the cost-utility of oncology treatments.
KW - European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30
KW - Quality of Life Utility-C10D
KW - cancer
KW - discrete choice experiment
KW - multiattribute utility theory
KW - utility valuation
UR - http://www.scopus.com/inward/record.url?scp=85103650957&partnerID=8YFLogxK
U2 - https://doi.org/10.1177/0272989X211003569
DO - https://doi.org/10.1177/0272989X211003569
M3 - Article
C2 - 33813946
SN - 0272-989X
VL - 41
SP - 485
EP - 501
JO - Medical decision making
JF - Medical decision making
IS - 4
ER -